Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes

International Journal of Clinical Practice

Volumn 65, Issue 2, 2011, Pages 165-171

  Levit, S ^a   Toledano, Y ^b   Wainstein, J ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b HILLEL YAFFE MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; HUMALOG MIX 50; INSULIN ASPART; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

AGED; BIPHASIC INSULINS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULINS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 78751497129     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02513.x     Document Type: Article

References (31)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
2. Yki-Järvinen H,. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
4. Peyrot M, Rubin RR, Lauritzen T, et al. Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study. Diabetologia 2006; 49: 279-88.
5. Mollema ED, Snoek FJ, AdÃr HJ, Heine RJ, van der Ploeg HM,. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001; 51: 665-72.
6. Heinemann L, Kapitza C, Starke AA, Heise T,. Time-action profile of the insulin analogue B28Asp. Diabet Med 1996; 13: 683-4.
7. Lindholm A, McEwen J, Riis AP,. Improved postprandial glycemic control with insulin aspart: a randomized doubleblind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801-5.
8. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-6.
9. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR,. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
10. Hirsch IB,. Insulin analogues. N Engl J Med 2005; 352: 174-83.
11. Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007; 18: 56-62.
12. Jacobsen LV, SÃgaard B, Riis A,. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamineretarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
13. Malone JK, Woodworth JR, Arora V, et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-30.
14. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I,. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-54.
15. Hermansen K, Colombo M, Storgaard H, Ostergaard A, Klendorf K, Madsbad S,. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-8.
16. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A,. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-9.
17. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A,. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-9.
18. Valensi P, Benroubi M, Borzi V, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009; 63: 522-31.
19. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008; 62: 1013-8.
20. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
21. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 527-32.
22. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47.
23. Davis T, Edelman SV,. Insulin therapy in type 2 diabetes. Med Clin North Am 2004; 88: 865-95.
24. Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R,. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005; 27 (Suppl. B): S75-88.
25. Avilés-Santa L, Sinding J, Raskin P,. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-8.
26. Bergenstal R, Johnson M, Whipple D, et al. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes [abstract 0347]. Diabetes 1998; 47 (Suppl. 1): A89.
27. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M,. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-96.
28. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-25.
29. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30.
30. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-44.
31. Hirsch IB,. Treatment of patients with severe insulin deficiency; what we have learned over the past 2 years. Am J Med 2004; 116 (Suppl. 3A): 17S-22S.